# Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

> **NCT03194646** · PHASE3 · TERMINATED · sponsor: **Bayer** · enrollment: 1272 (actual)

## Conditions studied

- Uterine Fibroids

## Interventions

- **DRUG:** Vilaprisan (BAY1002670)
- **DRUG:** Vilaprisan (BAY1002670)
- **DRUG:** Vilaprisan (BAY1002670)
- **OTHER:** Standard of care
- **DRUG:** Vilaprisan (BAY1002670)
- **DRUG:** Vilaprisan (BAY1002670)
- **DRUG:** Vilaprisan (BAY1002670)

## Key facts

- **NCT ID:** NCT03194646
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-30
- **Primary completion:** 2019-05-10
- **Final completion:** 2024-07-11
- **Target enrollment:** 1272 (ACTUAL)
- **Why stopped:** Due to a change in the development program, the study was closed prematurely.
- **Last updated:** 2025-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03194646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03194646, "Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03194646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*